These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 25560806)
1. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806 [TBL] [Abstract][Full Text] [Related]
2. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486 [TBL] [Abstract][Full Text] [Related]
3. ATR kinase inhibition sensitizes quiescent human cells to the lethal effects of cisplatin but increases mutagenesis. Hutcherson RJ; Kemp MG Mutat Res; 2019 Nov; 816-818():111678. PubMed ID: 31557599 [TBL] [Abstract][Full Text] [Related]
4. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma. Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208 [TBL] [Abstract][Full Text] [Related]
5. Feedback regulation of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 via ATM/Chk2 pathway contributes to the resistance of MCF-7 breast cancer cells to cisplatin. Lv J; Qian Y; Ni X; Xu X; Dong X Tumour Biol; 2017 Mar; 39(3):1010428317694307. PubMed ID: 28347251 [TBL] [Abstract][Full Text] [Related]
6. Changes in the response of MCF-7 cells to ionizing radiation after the combination of ATM and DNA-PK inhibition. Ćmielová J; Havelek R; Vávrová J; Řezáčová M Med Oncol; 2015 May; 32(5):138. PubMed ID: 25801233 [TBL] [Abstract][Full Text] [Related]
7. Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma. Beumer JH; Fu KY; Anyang BN; Siegfried JM; Bakkenist CJ BMC Cancer; 2015 Oct; 15():649. PubMed ID: 26438152 [TBL] [Abstract][Full Text] [Related]
8. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells. Moolmuang B; Ruchirawat M J Pharm Pharmacol; 2021 Mar; 73(1):40-51. PubMed ID: 33791808 [TBL] [Abstract][Full Text] [Related]
9. The development of ataxia telangiectasia mutated kinase inhibitors. Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084 [TBL] [Abstract][Full Text] [Related]
10. ATR inhibition sensitizes HPV Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392 [TBL] [Abstract][Full Text] [Related]
11. Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors. Wang WT; Catto JW; Meuth M Oncogene; 2015 May; 34(22):2887-96. PubMed ID: 25043304 [TBL] [Abstract][Full Text] [Related]
12. The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect. Zhang T; Shen Y; Chen Y; Hsieh JT; Kong Z Int J Radiat Biol; 2015 Apr; 91(4):368-78. PubMed ID: 25585815 [TBL] [Abstract][Full Text] [Related]
13. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814 [TBL] [Abstract][Full Text] [Related]
14. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342 [TBL] [Abstract][Full Text] [Related]
15. Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells. Dobler C; Jost T; Hecht M; Fietkau R; Distel L Cells; 2020 Sep; 9(9):. PubMed ID: 32883016 [TBL] [Abstract][Full Text] [Related]
16. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239 [TBL] [Abstract][Full Text] [Related]
17. [Employing DNA Damage Response Inhibitors to Enhance Chemosensitivity of Ovarian Carcinoma Cells]. Cai SY; Tang ZZ; Zeng M; Wang XJ; Lou JY; Liu C; Chen J Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 May; 47(3):316-20, 336. PubMed ID: 27468472 [TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair. Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031 [TBL] [Abstract][Full Text] [Related]
19. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells. Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014 [TBL] [Abstract][Full Text] [Related]
20. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation. Saha J; Wang M; Cucinotta FA DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]